Indian journal of Medical Biochemistry

Register      Login

VOLUME 23 , ISSUE 3 ( September-December, 2019 ) > List of Articles

RESEARCH ARTICLE

Can Gamma Glutamyl Transferase Serve as a Marker to Predict the Risk of Metabolic Syndrome in Patients with Type 2 Diabetes Mellitus?

CS Nagalakshmi, Basavaraj Savadi, NU Santhosh, Shaheen B Shaikh, Dinesh Javarappa

Keywords : Cardiovascular risk, Gamma glutamyl transferase, Laboratory research, Metabolic syndrome, Risk factors, Type 2 diabetes,Biochemical parameters

Citation Information : Nagalakshmi C, Savadi B, Santhosh N, Shaikh SB, Javarappa D. Can Gamma Glutamyl Transferase Serve as a Marker to Predict the Risk of Metabolic Syndrome in Patients with Type 2 Diabetes Mellitus?. Indian J Med Biochem 2019; 23 (3):347-349.

DOI: 10.5005/jp-journals-10054-0116

License: CC BY-NC 4.0

Published Online: 00-12-2019

Copyright Statement:  Copyright © 2019; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

Background and aim: Metabolic syndrome (MS) is a constellation of atherosclerotic risk factors and identifies patients who are at high risk for diabetes mellitus and cardiovascular disease (CVD). The interrelationship between gamma glutamyl transferase (GGT), obesity, and other metabolic disturbances raises the possibility that elevated GGT levels can help predict the risk of CVD in patients with MS and was proposed as a component of MS. Materials and methods: Patients with type 2 diabetes mellitus, presenting with central obesity, were enrolled as cases if they satisfied criteria for diagnosis of MS. Serum GGT levels were measured in cases as well as age- and gender-matched controls to assess the significance of difference, if any. Results: On analysis, we found an important association between serum GGT levels and MS, as shown by a significant difference in the levels of GGT in cases as compared to controls and the range of area under curve (AUC) for GGT was 0.648–0.827. Conclusion: Gamma glutamyl transferase may play a role in early diagnosis of MS with a high predictive value for both MS and risk for CVD, due to its association with insulin resistance. It is independent of other confounding factors. Due on its wide availability, simplicity, and universal standardization, GGT has the potential to be considered in algorithms for MS. Clinical significance: Including a raised GGT in the criteria for MS could increase its predictive nature for CVD. Considering the CVD risk, primary prevention may be emphasized in patients of MS with high GGT values.


PDF Share
  1. Bozbas H, Yıldırır A, Karacaglar E, et al. Increased serum gamma-glutamyltransferase activity in patients with metabolic syndrome. Turk Soc Card 2011;39(2):122–128.
  2. Ahmed A, Gupta N. Role of Gamma-Glutamyl Transferase in Diagnosis of Metabolic Syndrome in Indian adults: a Cross sectional Study. BMR Med 2015;1(1):1–4.
  3. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988;37:1595–1607. DOI: 10.2337/diab.37.12.1595.
  4. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991;14: 173–194. DOI: 10.2337/diacare.14.3.173.
  5. Kasapoglu B, Turkay C, Bayram Y, et al. Role of GGT in diagnosis of metabolic syndrome: a clinic-based cross-sectional survey. Indian J Med Res 2010;132:56–61.
  6. Whitfield JB. Gamma glutamyl transferase. Crit Rev Cl Lab Sci 2001;38(4):263–355. DOI: 10.1080/20014091084227.
  7. Irie M, Sohda T, Iwata K, et al. Levels of the oxidative stress marker γ-glutamyltranspeptidase at different stages of nonalcoholic fatty liver disease. J Int Med Res 2012;40(3):924–933. DOI: 10.1177/147323001204000311.
  8. Devers MC, Campbell S, Shaw J, et al. Should liver function tests be included in definitions of metabolic syndrome? Evidence from the association between liver function tests, components of metabolic syndrome and prevalent cardiovascular disease. Diabetic Med 2008;25:523–529. DOI: 10.1111/j.1464-5491.2008.02408.x.
  9. Andre P, Balkau B, Vol S, et al. DESIR Study Group. Gamma-glutamyltransferase activity and development of the metabolic syndrome (International Diabetes Federation Definition) in middle-aged men and women: Data from the Epidemiological Study on the Insulin Resistance Syndrome (DESIR) cohort. Diabetes Care 2007;30:2355–2361. DOI: 10.2337/dc07-0440.
  10. Ruttmann E, Brant LJ, Concin H, et al. γ-Glutamyltransferase as a risk factor for cardiovascular disease mortality. An epidemiological investigation in a cohort of 163944 Austrian adults. Circulation 2005;112:2130–2137. DOI: 10.1161/CIRCULATIONAHA.105.552547.
  11. Lee DS, Evans JC, Robins SJ, et al. Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study. Arterioscl Throm Vas 2007;27:127–133. DOI: 10.1161/01.ATV.0000251993.20372.40.
  12. Liu CF, Zhou WN, Fang NY. Gammaglutamyltransferase levels and risk of metabolic syndrome: a meta-analysis of prospective cohort studies. Int J Clin Pract 2012;66:692–698. DOI: 10.1111/j.1742-1241.2012.02959.x.
  13. Phepale K, Gokhroo A, Jain R, et al. Gamma glutamyl transferase as a diagnostic marker of metabolic syndrome. Indian J Bas App Med Res 2016;5(3):489–494.
  14. Tao L, Li X, Zhu H, et al. Association between γ-Glutamyl Transferase and Metabolic Syndrome: A Cross-Sectional Study of an Adult Population in Beijing. Int J Environ Res Public Health 2013;10: 5523–5540. DOI: 10.3390/ijerph10115523.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.